Haemonetics Corp., a blood management solutions company, has entered into a reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly owned subsidiary Alba Bioscience.
The arrangement provides Haemonetics with exclusive access to Alba’s comprehensive catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform. The arrangement includes future milestone payments in connection with the optimization of reagents for use in the Arryx system. Access to the reagents for commercialization is provided through a perpetual license.
Brian Concannon, president and CEO of Haemonetics, said: “Blood typing represents a future $1bn market opportunity for Haemonetics through the ongoing development of our Arryx technology. I am pleased to report this important milestone in our innovative nano-technology development program targeted at the blood diagnostics market. We look forward to updating our shareholders on our progress with Arryx at our upcoming investor day scheduled for May 13th.”
Paul Cowan, chairman of Quotient Biodiagnostics, said: “We are pleased to be working with Haemonetics on this exciting new technology platform for the transfusion diagnostics market. Alba’s portfolio of world-leading blood typing reagents will no doubt serve to facilitate and accelerate the development of the Arryx platform for Haemonetics.”
Alba Bioscience is a manufacturer and seller of critical raw materials and finished goods used for blood typing and screening. With over 15 products already licensed by the FDA (and further products in registration), Alba Bioscience is a supplier of FDA-licensed reagents and finished goods in the key North American market.